BiotechTube
Nivagen

Nivagen

Sacramento, United States· Est.
nivagen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Nivagen Pharmaceuticals is a vertically integrated specialty generics and CDMO company with a strategic focus on sterile injectables and 505(b)(2) development pathways. Its core assets include a 100,000 sq ft cGMP sterile manufacturing facility in Sacramento, CA, and a business model combining proprietary product development, out-licensing, and contract services. The company aims to address drug shortages and provide affordable, high-quality pharmaceuticals through a blend of internal development, global manufacturing partnerships, and 503B compounding for the institutional market.

Generic Drugs

Technology Platform

Advanced sterile manufacturing capabilities for injectables (IV bags, vials, PFS, cartridges) and expertise in the 505(b)(2) regulatory development pathway for modified drugs.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Significant opportunity exists in addressing persistent FDA drug shortages for sterile injectables through its 503B and generic manufacturing.
Growth in the biopharma CDMO sector, especially for US-based sterile production, provides a major service revenue stream.
The 505(b)(2) pathway allows for efficient development of differentiated specialty products with potential market exclusivity.

Risk Factors

High regulatory risk associated with sterile manufacturing and 503B compounding; any major FDA compliance issue could be catastrophic.
Intense competition in the generic injectables market from larger, established players pressures pricing and margins.
Operational execution risk across its three distinct business models (proprietary, CDMO, compounding) is complex and resource-intensive.

Competitive Landscape

Nivagen competes with large generic sterile injectable manufacturers (e.g., Hikma, Pfizer/Hospira, Fresenius Kabi), other 503B outsourcing facilities (e.g., Central Admixture Pharmacy Services, Fagron), and CDMOs specializing in sterile fill-finish (e.g., Baxter, Viatris, smaller niche CDMOs). Its differentiation lies in its vertical integration, US-based facility, and hybrid business model.

More companies in Small Molecule Drugs →More companies in United States →